Effectiveness of nephroprotective therapy in children with chronic pyelonephritis in the follow-up observation

Effectiveness of nephroprotective therapy in children with chronic pyelonephritis in the follow-up observation

Background. Timely correction of hemodynamic disorders in children with chronic pyelonephritis is a component of nephroprotection. Аngiotensin-converting enzyme inhibitors (ACEI) are the basis of renoprotective therapy. The purpose of the study was to evaluate the efficiency of nephroprotective ther...

Full description

Bibliographic Details
Main Author:	L.I. Vakulenko
Format:	Article
Language:	English
Published:	Publishing House Zaslavsky 2018-03-01
Series:	Zdorovʹe Rebenka
Subjects:	children chronic pyelonephritis renal hemodynamics daily blood pressure monitoring hypertension nephroprotection angiotensin-converting enzyme inhibitors
Online Access:	http://childshealth.zaslavsky.com.ua/article/view/129549

Similar Items

Violation of renal and peripheral hemodynamics in the development of cardiovascular disorders in children with chronic pyelonephritis
by: О.Ye. Аbaturov, et al.
Published: (2018-03-01)

Drug correction of endothelial dysfunction in children with chronic pyelonephritis
by: L.I. Vakulenko
Published: (2018-10-01)

Blockade of Rennin-Angiotensin system blunts the fibrotic response in experimental acute pyelonephritis
by: Singal A, et al.
Published: (2005-01-01)

From gene to protein - experimental and clinical studies of ACE2 in blood pressure control and arterial hypertension
by: Sheila K Patel, et al.
Published: (2014-06-01)

Nephroprotective strategy in the treatment of hypertension as a modern general medical problem
by: V. I. Podzolkov, et al.
Published: (2018-12-01)

The role of ultrasound dopplerography with an acutecaptopril test in assessing renal hemodynamics in chronicglomerulonephritis
by: S A Marlynov, et al.
Published: (2003-06-01)

Blood pressure reduction and clinical outcomes with angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers: protocol for a systematic review and meta-regression analysis
by: Jonathan A. Batty, et al.
Published: (2018-08-01)

ANGIOTENSIN II RECEPTOR ANTAGONISTS AND NEPHROPROTECTION: PLACE OF OLMESARTAN
by: V. V. Fomin
Published: (2013-08-01)

Microalbuminaria in hypertension: a review
by: Mahesh Bhattarai, et al.
Published: (2012-12-01)

Effect of an angiotensin-converting-enzyme inhibitor on the plasma concentration of cytokines and vasoactive molecules in patients with coronary heart disease and hypertension
by: A A Khadartsev, et al.
Published: (2017-12-01)

Anti-hyperuricemic and nephroprotective effect of geniposide in chronic hyperuricemia mice
by: Chao Liu, et al.
Published: (2019-10-01)

ARB I olmesartan interruption in cardiovascular and cardiorenal continuum: antihypertensive and nephroprotective effects (part 1)
by: M. G Bubnova
Published: (2014-12-01)

Features of Diurnal Rhythm of Blood Pressure at Chronic Pyelonephritis in Children
by: L.I. Vakulenko, et al.
Published: (2012-02-01)

Renin-angiotensin-aldosterone system blockers as the main pathogenetic approach of drug nephroprotection
by: N.D. Filipets, et al.
Published: (2019-02-01)

Blood pressure variability and risk for complications in arterial hypertension
by: O D Ostroumova
Published: (2012-10-01)

24-hour blood pressure profile in children with chronic pyelonephritis and chronic kidney disease stages I–III
by: L.I. Vakulenko
Published: (2019-08-01)

The problem of determining the efficiency of treatmentin the era of evidence-based medicine: international and domestic experience
by: S R Gilyarevsky
Published: (2014-06-01)

Incidence of Captopril–Induced Cough in Newly Diagnosed Hypertensive Patients: Incidence in an Outpatient Medical Clinic Population in Iran in 2011-2012
by: Javad Azimivaghar, et al.
Published: (2014-08-01)

Comparison of N-acetylcysteine and angiotensin converting enzyme inhibitors in blood pressure regulation in hypertensive patients
by: Arsalan Khaledifar, et al.
Published: (2015-01-01)

Renal Involvement in Systemic Sclerosis: An Update
by: Magdalena Chrabaszcz, et al.
Published: (2020-06-01)

Unmasking of a large pheochromocytoma by pyelonephritis
by: Igor Alexander Harsch, et al.
Published: (2019-11-01)

IRBESARTAN IN THE CLINICAL PRACTICE
by: V. I. Podzolkov, et al.
Published: (2015-09-01)

Serum angiotensin converting enzyme in pemphigus vulgaris
by: Reza M Robati, et al.
Published: (2014-01-01)

Effects of renin-angiotensin system blockers on the risk and outcomes of severe acute respiratory syndrome coronavirus 2 infection in patients with hypertension
by: Jinwoo Lee, et al.
Published: (2021-03-01)

COVID-19 morbidity and mortality associated with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers use among 14,129 patients with hypertension from a US integrated healthcare system
by: Jaejin An, et al.
Published: (2021-06-01)

Resistance to antihypertensive drugs targeting Renin-Angiotensin-Aldosterone-System in cancer patients: a case series
by: Mishita Goel, et al.
Published: (2020-08-01)

What is the optimal choice of antihypertensive therapy based on: the class-specific effects or special properties of a drug?
by: T V Adasheva, et al.
Published: (2013-09-01)

Hypertension, renin-angiotensin-aldosterone-system-blocking agents, and COVID-19
by: Si-Hyuck Kang, et al.
Published: (2021-06-01)

Associations Between the Use of Renin–Angiotensin System Inhibitors and the Risks of Severe COVID-19 and Mortality in COVID-19 Patients With Hypertension: A Meta-Analysis of Observational Studies
by: Xiao-Ce Dai, et al.
Published: (2021-04-01)

Renal dysfunction in patients with cardiovascular disease. The effects of blockers of the renin-angiotensinaldosterone system
by: T. N Zvereva, et al.
Published: (2016-03-01)

Effect of Onopordon acanthium L. as Add on Antihypertensive Therapy in Patients with Primary Hypertension Taking Losartan: a Pilot Study
by: Roshanak Ghods, et al.
Published: (2018-03-01)

Hypogonadal hypertension in male Sprague-Dawley rats is renin-angiotensin system-dependent: role of endogenous androgens
by: Andrea E. Hanson, et al.
Published: (2020-08-01)

Long-term antihypertensive effect of a soluble cocoa fiber product in spontaneously hypertensive rats
by: Sandra Fernández-Vallinas, et al.
Published: (2016-05-01)

Egg-derived ACE-inhibitory peptides IQW and LKP reduce blood pressure in spontaneously hypertensive rats
by: Kaustav Majumder, et al.
Published: (2015-03-01)

Selection of antihypertensive drugs from the perspective of clinical pharmacology
by: Victor Ghicavii, et al.
Published: (2018-02-01)

Analysis of the antihypertensive drugs prescription on the outpatient level
by: A. Yа. Bazylevych
Published: (2015-10-01)

Antihypertensive Effects of Polyphenolic Extract from Korean Red Pine (<i>Pinus densiflora</i> Sieb. et Zucc.) Bark in Spontaneously Hypertensive Rats
by: Kwan Joong Kim, et al.
Published: (2020-04-01)

Angiotensin-converting Enzyme Inhibitors: Can it be a Potential Treatment of Infantile Hemangioma
by: Archika Gupta, et al.
Published: (2021-01-01)

Angiotensin II and COVID-19. Secrets of interactions
by: A. O. Konradi, et al.
Published: (2020-05-01)

Vasoprotection and nephroprotection: links of the same chain
by: N. Sh. Zagidullin, et al.
Published: (1970-01-01)